• Skip to primary navigation
  • Skip to main content
  • Skip to footer

WallachBeth

The leading provider of institutional execution services

  • Who We Are
  • Expertise
    • Execution
    • Consulting
    • Capital Markets
  • News
  • Contact

In the News

ETFs, WallachBeth Capital / August 2, 2022

Andy McOrmond Joined CNBC’s ETF Edge

Andy McOrmond, Managing Director, joined Bob Pisani on CNBC’s ETF Edge to discuss his views on ETF trends this summer, and what traders will be up to in …

[Read more...] about Andy McOrmond Joined CNBC’s ETF Edge

Capital Markets, Healthcare / May 17, 2022

WallachBeth Announces Completion of ABVC BioPharma, Inc. (Nasdaq: ABVC) $4.22 Million Registered Direct Offering

WallachBeth announced the completion of the purchase and sale of 2,000,000 shares of common stock of ABVC BioPharma, Inc. (Nasdaq: ABVC), and warrants to …

[Read more...] about WallachBeth Announces Completion of ABVC BioPharma, Inc. (Nasdaq: ABVC) $4.22 Million Registered Direct Offering

Capital Markets, Healthcare / April 13, 2022

WallachBeth Capital Announces Purchase and Sale of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) $5.8 Million Registered Direct Offering Priced At-The-Market

WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that LIXTE Biotechnology Holdings, Inc. …

[Read more...] about WallachBeth Capital Announces Purchase and Sale of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) $5.8 Million Registered Direct Offering Priced At-The-Market

« Previous Page
Next Page »

Footer

Contact Us

646.237.8585
info@wallachbeth.com

About Us

WallachBeth Capital is a leading provider of institutional execution services, offering our clients a full spectrum of solutions to help them navigate increasingly complex markets.

Find out more

Follow Us

  • Email
  • LinkedIn

Privacy Policy SEC Rule 606 Regulation SHO FINRA's BrokerCheck Business Continuity Form CRS FINRA SiPC